Clarity Pharmaceuticals Ltd. (AU:CU6) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Clarity Pharmaceuticals Ltd. is set to launch a crucial Phase III trial for its prostate cancer diagnostic agent, 64Cu-SAR-bisPSMA, following promising discussions with the U.S. FDA. The trial, named AMPLIFY, will evaluate the agent’s efficacy in detecting recurrent prostate cancer in a non-randomised, single-arm study of approximately 220 patients. This follows successful prior trials which demonstrated significant improvements over standard imaging agents, potentially offering enhanced detection capabilities and improved treatment outcomes for patients.
For further insights into AU:CU6 stock, check out TipRanks’ Stock Analysis page.